Expressions of miR-29a, TNF-Α and Vascular Endothelial Growth Factor in Peripheral Blood of Pulmonary Tuberculosis Patients and Their Clinical Significance
Background: To investigate the expression levels of miRNA-29a (miR-29a), tumor necrosis factor-α (TNF-α) and vascular endothelial growth factor (VEGF) in peripheral blood of pulmonary tuberculosis patients and their correlation with clinical and pathological features.
Methods: A prospective analysis was performed on 192 pulmonary tuberculosis patients (pulmonary tuberculosis group) and 186 healthy patients (control group) who were admitted to Beijing Chest Hospital, Capital Medical University, Beijing, China from Jun 2015 to Jun 2019. Real-time quantitative PCR was used to detect the expression levels of miR-29a, and ELISA to detect the concentrations of TNF-α and VEGF in serum. The diagnostic value of miR-29a, TNF-α and VEGF in tuberculosis was analyzed using receiver operating characteristic curve (ROC). The correlation of the expression levels of miR-29a, TNF-α and VEGF with gender, age, low-grade fever, expectoration, hemoptysis and pulmonary tuberculosis classification was analyzed.
Results: The expression levels of miR-29a, TNF-α and VEGF in pulmonary tuberculosis group were significantly higher than those in control group (P<0.001). The area under curves of miR-29a, TNF-α, and VEGF were 0.818, 0.743, and 0.805, respectively. miR-29a was closely correlated with low-grade fever, expectoration, hemoptysis and pulmonary tuberculosis classification (P<0.050). TNF-α and VEGF were closely correlated with patient age, low-grade fever, expectoration, hemoptysis and pulmonary tuberculosis classification (P<0.050).
Conclusion: Highly expressed in pulmonary tuberculosis patients, TNF-α and VEGF are closely correlated with the disease progression of patients, expected to become targets for the diagnosis and treatment of pulmonary tuberculosis in the future.
2. Zak DE, Penn-Nicholson A, Scriba TJ, et al (2016). A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, 387: 2312-2322.
3. Houben RM, Dodd PJ (2016). The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 13: e1002152.
4. Nikolayevskyy V, Kranzer K, Niemann S, Drobniewski F (2016). Whole genome sequencing of Mycobacterium tuberculosis for detection of recent transmission and tracing outbreaks: A systematic review. Tuberculosis (Edinb), 98: 77-85.
5. Hunter RL (2016). Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis. Tuberculosis (Edinb), 97: 8-17.
6. Lifson AR, Thai D, O'Fallon A, et al(2002). Prevalence of tuberculosis, hepatitis B virus, and intestinal parasitic infections among refugees to Minnesota. Public Health Rep, 117: 69-77.
7. Francisco-Cruz A, Mata-Espinosa D, Ramos-Espinosa O, et al (2016). Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis. Tuberculosis (Edinb), 100: 5-14.
8. Wilczynska A, Bushell M (2015). The complexity of miRNA-mediated repression. Cell Death Differ, 22: 22-33.
9. Yuan R, Zhi Q, Zhao H, et al (2015). Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma. Tumour Biol, 36: 3093-3100.
10. Yen CS, Su ZR, Lee YP, et al (2016). miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol, 22: 5183-5192.
11. Akdis M, Aab A, Altunbulakli C, et al (2016). Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases. J Allergy Clin Immunol, 138: 984-1010.
12. Ferrara N, Adamis AP (2016). Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov, 15: 385-403.
13. Alatas F, Alatas O, Metintas M, et al (2004). Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest, 125: 2156-2159.
14. Nakiyingi L, Nankabirwa H, Lamorde M (2013). Tuberculosis diagnosis in resource-limited settings: Clinical use of GeneXpert in the diagnosis of smear-negative PTB: a case report. Afr Health Sci, 13: 522-524.
15. Kumar NP, Moideen K, Viswanathan V, et al (2016). Effect of standard tuberculosis treatment on naive, memory and regulatory T-cell homeostasis in tuberculosis-diabetes co-morbidity. Immunology, 149: 87-97.
16. Toulza F, Tsang L, Ottenhoff TH, et al (2016). Mycobacterium tuberculosis-specific CD4+ T-cell response is increased, and Treg cells decreased, in anthelmintic-treated patients with latent TB. Eur J Immunol, 46: 752-761.
17. Munagala R, Aqil F, Gupta RC (2016). Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour Biol, 37: 10703-10714.
18. Alipoor SD, Adcock IM, Garssen J, et al (2016). The roles of miRNAs as potential biomarkers in lung diseases. Eur J Pharmacol, 791: 395-404.
19. Fan L, Qi H, Teng J, Su B, et al (2016). Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer. Tumour Biol, 37: 7777-7784.
20. Snyder-Talkington BN, Dong C, Sargent LM, et al (2016). mRNAs and miRNAs in whole blood associated with lung hyperplasia, fibrosis, and bronchiolo-alveolar adenoma and adenocarcinoma after multi-walled carbon nanotube inhalation exposure in mice. J Appl Toxicol, 36: 161-174.
21. Afum-Adjei Awuah A, Ueberberg B, Owusu-Dabo E, et al (2014). Dynamics of T-cell IFN-gamma and miR-29a expression during active pulmonary tuberculosis. Int Immunol, 26: 579-582.
22. Dymicka-Piekarska V, Korniluk A, Gryko M, et al (2014). Potential role of soluble CD40 ligand as inflammatory biomarker in colorectal cancer patients. Int J Biol Markers, 29: e261-267.
23. Simons M, Gordon E, Claesson-Welsh L (2016). Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol, 17: 611-625.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.